Bio-Rad Laboratories (BIO) Net Cash Flow Growth (3y) (2012 - 2026)
Bio-Rad Laboratories (BIO) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | -9.45% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 60.16% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | -85.83% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 43.26% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -26.30% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 21.48% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -127.77% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 269.22% |
| 10 | Bio-Rad Laboratories | 10.07 Bn | 8.45 Bn | 345.80 Mn | 27.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.19% |
| Mar 31, 2026 | -42.78% |
| Dec 31, 2025 | 59.33% |
| Sep 30, 2025 | 31.90% |
| Jun 30, 2025 | 13.99% |
| Mar 31, 2025 | -52.36% |
| Dec 31, 2024 | 29.51% |
| Sep 30, 2024 | -55.32% |
| Jun 30, 2024 | -36.13% |
| Mar 31, 2024 | 14.20% |
| Dec 31, 2023 | 36.75% |
| Sep 30, 2023 | -35.26% |
| Jun 30, 2023 | -421.61% |
| Mar 31, 2023 | 38.60% |
| Dec 31, 2022 | -39.22% |
| Sep 30, 2022 | -80.74% |
| Jun 30, 2022 | -54.73% |
| Mar 31, 2022 | 144.00% |
| Dec 31, 2021 | -399.54% |
| Sep 30, 2021 | 63.37% |